ClinicalTrials.gg
TerminatedNCT03351244Updated May 14, 2025Results posted

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

A Phase 2 interventional study of BI 409306 and Placebo in Schizophrenia, sponsored by Boehringer Ingelheim. Terminated at 59 sites in 7 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Why this study was terminated
disruption due to COVID-19

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
264
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies in Schizophrenia by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Schizophrenia · Boehringer Ingelheim.

Enrollment
7th of 11
264 · median 509
Started
2017
the only one that year
Phase 2
4 of 11
none open now
Registered
5th of 11
by date

Among the 11 studies in Schizophrenia by Boehringer Ingelheim, this one is the 7th largest by enrollment, is the only one that started in 2017, is one of 4 in phase 2, and was the 5th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 11 studies in Schizophrenia by Boehringer Ingelheim is open now. The open studies under Schizophrenia, anywhere →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Schizophrenia by Boehringer Ingelheim as a file.
02

Study summary

The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment. The study is designed to show superiority of BI 409306 over placebo in preventing relapse of schizophrenia symptoms.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) diagnosis of schizophrenia >= one year prior to randomisation.
  • Outpatients in the stable phase of illness, as assessed by the investigator after review of medical records or documented discussion with treating clinician.
  • Patients currently taking a stable dose of antipsychotic medication(s) for at least 12 weeks prior to randomisation.
  • Detectable level of current antipsychotic medication(s) in plasma from blood drawn at Visit 1 (unless no assay is available for the antipsychotic(s) currently prescribed).
  • Patients who have experienced at least 2 relapses within the past 5 years or at least 1 relapse if they were diagnosed less than 3 years ago. Relapse is defined as the patient having any of the following using the above number of relapses and time frames:

    • Hospitalization for psychosis (involuntary or voluntary admission), intensive outpatient therapy or use of home treatment as an alternative to hospitalization (verified via medical record).
    • Emergency Department visit for worsening schizophrenia symptoms (verified via medical record).
    • Deliberate self-injury and/or violent behaviour resulting in significant injury to another person or property (verified by police record or treating mental health provider written record or documented phone conversation).
    • Change in the patient's antipsychotic medication or increase in antipsychotic medication dosage due to worsening of schizophrenia symptoms (verified by pharmacy records or treating mental health provider written record or documented phone conversation).
  • Clinical Global Impressions-Severity (CGI-S) score ≤4 at Visit 1 and 2.
  • Positive and Negative Syndrome Scale (PANSS) total score \<80 and a score of ≤ 4 on individual PANSS items conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content at Visit 1.
  • Of full age (according to local legislation, usually ≥ 18 years) and ≤ 55 years at the time of .
  • Patients must have an identified informant who will be consistent throughout the study.
  • Patients who report living at the same address for the 3 months prior to randomisation.
  • Male or female patients.

    -- Female patients of must be ready and able to use highly effective methods of per International Conference on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. Patients must agree to use birth control throughout the trial and for at least 28 days after treatment has ended. Acceptable methods of birth control include combined estrogen-progestin oral, intravaginal or transdermal contraceptives, progestogen-only oral, injectable or implantable contraceptives, intrauterine devices (IUDs), intrauterine hormone releasing systems (IUSs), bilateral tubal occlusion, vasectomized sexual partner, and complete sexual abstinence (if acceptable by local health authorities) is allowed when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptom-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

  • Male patients who are able to father a child must be ready and able to be abstinent or use adequate contraception for the duration of study participation and for at least 28 days after treatment has ended.
  • Signed and dated written informed consent in accordance with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial. If the patient has a legal representative, then this legal representative must give written informed consent as well.

Exclusion criteria

Exclusion criteria:

  • Patients treated with more than two antipsychotic medications (including more than two dosage forms).
  • Patients who are currently being treated with clozapine, or who have been treated with clozapine in the past 5 years.
  • Patients with a categorical diagnosis of another current major psychiatric disorder per the Mini-international neuropsychiatric Interview (M.I.N.I.).
  • Homicidal behaviour (in the investigator's judgement) in the past 2 years.
  • Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
  • Any suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale (CSSRS) in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent).
  • In the judgment of the investigator, any finding from the physical examination or laboratory value deviating from normal or any evidence of a clinically significant concomitant disease or any other clinical condition that would jeopardize a patient's safety while participating in the clinical trial.
  • Other known neurological diseases (including but not limited to any kind of seizures or stroke).
  • Any documented active or suspected or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix.
  • Planned elective surgery requiring general anesthesia, or hospitalization for more than 1 day during the study period.
  • Significant history of drug or alcohol dependence or abuse (Substance Use Disorder as defined in , 5th Edition (DSM-5) or ICD-10) within the last six months prior to . (Not including caffeine or nicotine).
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
  • Patients taking strong or moderate CYP1A2 inhibitors who are also a CYP2C19 Poor Metabolizer (PM). Patients taking medication known to be strong or moderate inhibitors of CYP1A2 must be prospectively genotyped to ensure they are not poor metabolizers of CYP2C19. (A list of CYP1A2 and CYP2C19 inhibitors can be found in the Investigator Site File (ISF)).
  • Patients taking strong or moderate CYP1A2 inhibitors who are also taking concomitant strong or moderate CYP2C19 inhibitors. (A list of CYP1A2 and CYP2C19 inhibitors can be found in the ISF)
  • Patients with a history of moderate to severe hepatic impairment ( B / C).
  • Patients with a history of moderate to severe renal impairment (Stage 3 - 5).
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
  • In the judgment of the investigator, inability of the patient to comply with the clinical trial procedures.
  • Currently enrolled in another device or drug study, or less than 6 months from Visit 1 since ending another investigational device or drug study(s), or participation in > 2 investigational drug clinical trials in the past 2 years.
  • Previous randomisation in any BI 409306 study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
264 participants (actual)

Study arms

  • Experimental
    BI 409306 50 mg

    1 film-coated tablet of 50 milligrams (mg) of BI 409306 plus 1 tablet of 25 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.

    Drug: BI 409306

  • Experimental
    BI 409306 25 mg

    1 film-coated tablet of 25 milligrams (mg) of BI 409306 plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.

    Drug: BI 409306

  • Placebo comparator
    Placebo

    1 film-coated tablet of 25 milligrams (mg) of matching Placebo plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.

    Drug: Placebo

Interventions

  • 28 week treatment period

  • DrugPlacebo

    28 week treatment period

06

What researchers measure

Primary outcomes

  1. Incidence Rate of First Relapse After 28 Weeks of Treatment

    The incidence rate of first relapse after 28 weeks of treatment is reported. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.

    Time frame: 28 weeks

Secondary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Symptoms Score After 28 Weeks of Treatment

    Positive and Negative Syndrome Scale (PANSS): assesses the severity of psychotic symptoms and progression of disease. The PANSS positive symptoms score is the sum of scores from 7 Items where each item has a minimum score 1 (better outcome) and maximum score 7 (worse outcome). The PANSS positive symptoms score ranges from 7 (less severe the disease) to 49 (more severe the disease).

    Time frame: At baseline and at Week 28.

  2. Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 28 Weeks of Treatment

    Clinical Global Impressions-Severity (CGI-S): One-item evaluation completed by the clinician to measure the severity of psychopathology. The CGI-S score ranges from 1 (normal) through to 7 (most severely ill). The higher the score, the worse the psychopathology.

    Time frame: At baseline and at Week 28

  3. Patient Global Impressions-Improvement (PGI-I) Scale Score After 28 Weeks of Treatment

    Patient Global Impressions-Improvement (PGI-I): One-item evaluation completed by the patient to assess their overall evaluation of his/her status compared to how they felt at randomisation. The PGI-I score ranges from 1 (Very much better) through to 7 (Very much worse). The higher the score, the worse the improvement.

    Time frame: At Week 28

  4. Incidence Rate of Suicidal Ideation and Behaviour (Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)) After 28 Weeks of Treatment

    Columbia Suicide Severity Rating Scale (C-SSRS): suicide risk assessment. At a minimum, the interview consists of 2 screening questions related to suicidal ideation and 4 related to suicidal behavior, and may be expanded to up to 17 items in case of positive responses. Free text entries are allowed. Suicidal behavior is collected in nominal scale as presence/absence of actual attempts, non-suicidal self-injurious behavior, interrupted attempts, aborted attempts, preparatory acts or behavior, and any suicidal behavior. Suicidal ideation is rated on a 6-point scale from 0 (No ideation present) to 5 (Active ideation with plan and intent). A score of 4 or 5 on this scale indicates serious suicidal ideation. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.

    Time frame: 28 weeks

  5. Change From Baseline in Personal and Social Performance Scale (PSP) Score After 28 Weeks of Treatment

    Personal and Social Performance scale (PSP): The PSP is a 100-point, single item, clinician rated scale to assess 4 domains of social functioning (Four domains over the past month: (1) socially useful activities, (2) personal and social relationships, (3) self-care and (4) disturbing and aggressive behaviors.) in patients with schizophrenia. The PSP score is a single score ranging from 1 to 100. Higher scores represent better personal and social functioning.

    Time frame: At baseline and at Week 28

  6. Incidence Rate of New Prescription or Increase in Dose of an Ongoing Antipsychotic Medication

    The incidence rate of new prescription or increase in dose of an ongoing antipsychotic medication is reported. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.

    Time frame: 28 weeks

07

Results

Posted Apr 4, 2022
Limitations and caveats
The study was terminated due to sponsor decision. The planned number of participants to be recruited was not reached.

Participant flow

This Phase II trial aimed to evaluate the impact of 28-week treatment with BI 409306 (added to standard antipsychotic medication) compared with placebo on preventing relapse in patients with schizophrenia.

Participant flow — Overall Study
MilestoneBI 409306 25 mgBI 409306 50 mgPlacebo
Started898887
Completed624853
Not completed274034
Withdrew: Adverse event71112
Withdrew: Investigator's decision002
Withdrew: System error002
Withdrew: Covid-19 restrictions301
Withdrew: Non-compliance250
Withdrew: Withdrawal by subject111613
Withdrew: Lost to follow-up264
Withdrew: Protocol violation220

Outcome measures

PrimaryIncidence Rate of First Relapse After 28 Weeks of Treatment

The incidence rate of first relapse after 28 weeks of treatment is reported. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.

Time frame:
28 weeks
Reported as:
Number · Events per patient-years
Incidence Rate of First Relapse After 28 Weeks of Treatment
Events per patient-yearsBI 409306 25 mgBI 409306 50 mgBI 409306 PooledPlacebo
Incidence Rate of First Relapse After 28 Weeks of Treatment0.5270.4340.4820.496
Statistical analysis
  • BI 409306 25 mg vs Placebo · Regression, Cox · p = 0.7735 · Hazard ratio (hr): 1.097 · 95% CI 0.585 to 2.056The model included the treatment effect as the only covariate and was stratified by country.
  • BI 409306 50 mg vs Placebo · Regression, Cox · p = 0.7809 · Hazard ratio (hr): 0.910 · 95% CI 0.468 to 1.770The model included the treatment effect as the only covariate and was stratified by country.
  • BI 409306 Pooled vs Placebo · Regression, Cox · p = 0.9862 · Hazard ratio (hr): 1.005 · 95% CI 0.576 to 1.753The model included the treatment effect as the only covariate and was stratified by country.
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Symptoms Score After 28 Weeks of Treatment

Positive and Negative Syndrome Scale (PANSS): assesses the severity of psychotic symptoms and progression of disease. The PANSS positive symptoms score is the sum of scores from 7 Items where each item has a minimum score 1 (better outcome) and maximum score 7 (worse outcome). The PANSS positive symptoms score ranges from 7 (less severe the disease) to 49 (more severe the disease).

Time frame:
At baseline and at Week 28.
Reported as:
Mean · Score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Symptoms Score After 28 Weeks of Treatment
Score on a scaleBI 409306 25 mgBI 409306 50 mgBI 409306 PooledPlacebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Symptoms Score After 28 Weeks of Treatment-0.54 (-1.370 to 0.294)-0.71 (-1.641 to 0.224)-0.61 (-1.231 to 0.005)-0.92 (-1.769 to -0.070)
Statistical analysis
  • BI 409306 25 mg vs Placebo · Mixed model with repeated measurements · p = 0.5289 · Placebo-corrected adjusted mean: 0.38 · 95% CI -0.809 to 1.570The analysis included the fixed, categorical effects of treatment at each visit, and the fixed continuous effects of baseline at each visit.
  • BI 409306 50 mg vs Placebo · Mixed model with repeated measurements · p = 0.7440 · Placebo-corrected adjusted mean: 0.21 · 95% CI -1.055 to 1.475The analysis included the fixed, categorical effects of treatment at each visit, and the fixed continuous effects of baseline at each visit.
  • BI 409306 Pooled vs Placebo · Mixed model with repeated measurements · p = 0.5659 · Placebo-corrected adjusted mean: 0.31 · 95% CI -0.745 to 1.358The analysis included the fixed, categorical effects of treatment at each visit, and the fixed continuous effects of baseline at each visit.
SecondaryChange From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 28 Weeks of Treatment

Clinical Global Impressions-Severity (CGI-S): One-item evaluation completed by the clinician to measure the severity of psychopathology. The CGI-S score ranges from 1 (normal) through to 7 (most severely ill). The higher the score, the worse the psychopathology.

Time frame:
At baseline and at Week 28
Reported as:
Mean · Score on a scale
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 28 Weeks of Treatment
Score on a scaleBI 409306 25 mgBI 409306 50 mgBI 409306 PooledPlacebo
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 28 Weeks of Treatment-0.15 ± 0.758-0.22 ± 0.839-0.18 ± 0.791-0.22 ± 0.718
SecondaryPatient Global Impressions-Improvement (PGI-I) Scale Score After 28 Weeks of Treatment

Patient Global Impressions-Improvement (PGI-I): One-item evaluation completed by the patient to assess their overall evaluation of his/her status compared to how they felt at randomisation. The PGI-I score ranges from 1 (Very much better) through to 7 (Very much worse). The higher the score, the worse the improvement.

Time frame:
At Week 28
Reported as:
Mean · Score on a scale
Patient Global Impressions-Improvement (PGI-I) Scale Score After 28 Weeks of Treatment
Score on a scaleBI 409306 25 mgBI 409306 50 mgBI 409306 PooledPlacebo
Patient Global Impressions-Improvement (PGI-I) Scale Score After 28 Weeks of Treatment2.61 ± 1.3282.96 ± 1.1972.76 ± 1.2802.94 ± 1.190
SecondaryIncidence Rate of Suicidal Ideation and Behaviour (Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)) After 28 Weeks of Treatment

Columbia Suicide Severity Rating Scale (C-SSRS): suicide risk assessment. At a minimum, the interview consists of 2 screening questions related to suicidal ideation and 4 related to suicidal behavior, and may be expanded to up to 17 items in case of positive responses. Free text entries are allowed. Suicidal behavior is collected in nominal scale as presence/absence of actual attempts, non-suicidal self-injurious behavior, interrupted attempts, aborted attempts, preparatory acts or behavior, and any suicidal behavior. Suicidal ideation is rated on a 6-point scale from 0 (No ideation present) to 5 (Active ideation with plan and intent). A score of 4 or 5 on this scale indicates serious suicidal ideation. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.

Time frame:
28 weeks
Reported as:
Number · Events per patient-years
Incidence Rate of Suicidal Ideation and Behaviour (Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)) After 28 Weeks of Treatment
Events per patient-yearsBI 409306 25 mgBI 409306 50 mgBI 409306 PooledPlacebo
Incidence Rate of Suicidal Ideation and Behaviour (Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)) After 28 Weeks of Treatment0.0700.0770.0730.071
Statistical analysis
  • BI 409306 25 mg vs Placebo · Regression, Cox · p = 0.9938 · Hazard ratio (hr): 1.006 · 95% CI 0.203 to 4.989The model included the treatment effect as the only covariate and was stratified by country.
  • BI 409306 50 mg vs Placebo · Regression, Cox · p = 0.8930 · Hazard ratio (hr): 1.116 · 95% CI 0.225 to 5.531The model included the treatment effect as the only covariate and was stratified by country.
  • BI 409306 Pooled vs Placebo · Regression, Cox · p = 0.9360 · Hazard ratio (hr): 1.058 · 95% CI 0.265 to 4.233The model included the treatment effect as the only covariate and was stratified by country.
SecondaryChange From Baseline in Personal and Social Performance Scale (PSP) Score After 28 Weeks of Treatment

Personal and Social Performance scale (PSP): The PSP is a 100-point, single item, clinician rated scale to assess 4 domains of social functioning (Four domains over the past month: (1) socially useful activities, (2) personal and social relationships, (3) self-care and (4) disturbing and aggressive behaviors.) in patients with schizophrenia. The PSP score is a single score ranging from 1 to 100. Higher scores represent better personal and social functioning.

Time frame:
At baseline and at Week 28
Reported as:
Mean · Score on a scale
Change From Baseline in Personal and Social Performance Scale (PSP) Score After 28 Weeks of Treatment
Score on a scaleBI 409306 25 mgBI 409306 50 mgBI 409306 PooledPlacebo
Change From Baseline in Personal and Social Performance Scale (PSP) Score After 28 Weeks of Treatment2.8 ± 8.82.4 ± 9.42.6 ± 9.13.0 ± 10.2
SecondaryIncidence Rate of New Prescription or Increase in Dose of an Ongoing Antipsychotic Medication

The incidence rate of new prescription or increase in dose of an ongoing antipsychotic medication is reported. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.

Time frame:
28 weeks
Reported as:
Number · Events per patient-years
Incidence Rate of New Prescription or Increase in Dose of an Ongoing Antipsychotic Medication
Events per patient-yearsBI 409306 25 mgBI 409306 50 mgBI 409306 PooledPlacebo
Incidence Rate of New Prescription or Increase in Dose of an Ongoing Antipsychotic Medication0.1680.1300.1490.217
Statistical analysis
  • BI 409306 25 mg vs Placebo · Regression, Cox · p = 0.6362 · Hazard ratio (hr): 0.788 · 95% CI 0.293 to 2.118The model included the treatment effect as the only covariate and was stratified by country.
  • BI 409306 50 mg vs Placebo · Regression, Cox · p = 0.3782 · Hazard ratio (hr): 0.612 · 95% CI 0.205 to 1.826The model included the treatment effect as the only covariate and was stratified by country.
  • BI 409306 Pooled vs Placebo · Regression, Cox · p = 0.4253 · Hazard ratio (hr): 0.703 · 95% CI 0.296 to 1.671The model included the treatment effect as the only covariate and was stratified by country.

Adverse events

Collected over All-cause mortality: From first dose until withdraw or end of 1-week taper period + 3-week follow-up period, up to 32 weeks. Serious (non-serious) adverse events: From first dose until withdraw or end of 1-week taper period + 1-week residual effect period, up to 30 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BI 409306 25 mg0/89 (0%)9/89 (10.1%)30/89 (33.7%)
BI 409306 50 mg1/88 (1.1%)7/88 (8%)25/88 (28.4%)
Placebo0/87 (0%)12/87 (13.8%)19/87 (21.8%)
Total1/264 (0.4%)28/264 (10.6%)74/264 (28%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventBI 409306 25 mgBI 409306 50 mgPlaceboTotal
SchizophreniaPsychiatric disorders2/891/884/877/264
PneumoniaInfections and infestations0/890/883/873/264
Suicidal ideationPsychiatric disorders3/890/882/875/264
IleusGastrointestinal disorders0/890/881/871/264
Wound infectionInfections and infestations0/890/881/871/264
Skin abrasionInjury, poisoning and procedural complications0/890/881/871/264
AgitationPsychiatric disorders0/890/881/871/264
DelusionPsychiatric disorders0/890/881/871/264
Depression suicidalPsychiatric disorders0/890/881/871/264
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/890/881/871/264
Most frequent other events
Most frequent other events
EventBI 409306 25 mgBI 409306 50 mgPlaceboTotal
PhotophobiaEye disorders3/898/881/8712/264
NasopharyngitisInfections and infestations7/895/887/8719/264
HeadacheNervous system disorders6/897/884/8717/264
InsomniaPsychiatric disorders5/896/880/8711/264
SchizophreniaPsychiatric disorders6/894/882/8712/264
VomitingGastrointestinal disorders1/891/885/877/264
SomnolenceNervous system disorders5/893/883/8711/264

Baseline characteristics

Treated set (TS): the TS includes all patients who were randomised and were documented to have taken at least 1 dose of trial drug.

Age, Continuous
Age, Continuous(Years)BI 409306 25 mgBI 409306 50 mgPlaceboTotal
Mean38.4 ± 9.841.9 ± 9.640.5 ± 9.840.3 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)BI 409306 25 mgBI 409306 50 mgPlaceboTotal
Female29363297
Male605255167
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BI 409306 25 mgBI 409306 50 mgPlaceboTotal
Hispanic or Latino10151540
Not Hispanic or Latino756968212
Unknown or Not Reported44412
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BI 409306 25 mgBI 409306 50 mgPlaceboTotal
American Indian or Alaska Native0000
Asian23202063
Native Hawaiian or Other Pacific Islander0202
Black or African American363732105
White23242572
More than one race1124
Unknown or Not Reported64818
08

Study locations

59 sites
  • Alea Research
    Phoenix, Arizona 85012, United States
  • ATP Clinical Research, Inc.
    Costa Mesa, California 92626, United States
  • Collaborative Neuroscience Network, LLC (CNS)
    Garden Grove, California 92845, United States
  • Behavioral Research Specialists, LLC
    Glendale, California 91206, United States
  • Synergy East
    Lemon Grove, California 91945, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Excell Research Inc.
    Oceanside, California 92056, United States
  • Orange County Neuropsychiatric Research Center LLC
    Orange, California 92868, United States
  • Collaborative Neuroscience Network, LLC (CNS)
    Torrance, California 90502, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Reliable Clinical Research
    Hialeah, Florida 33012, United States
  • Meridien Research
    Maitland, Florida 32751, United States
  • Behavioral Clinical Research, Inc.
    North Miami, Florida 33161, United States
  • Meridien Research
    Orlando, Florida 32810, United States
  • Atlanta Center
    Atlanta, Georgia 30331, United States
  • Alam Medical Research, Inc.
    Chicago, Illinois 60612, United States
  • Lake Charles Clinical Trials LLC
    Lake Charles, Louisiana 70629, United States
  • Clinical Trials of America, LLC
    Monroe, Louisiana 71201, United States
  • Michigan Clinical Research Institute PC
    Ann Arbor, Michigan 48105, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • St. Charles Psychiatric Associates & Midwest Research Group
    Saint Charles, Missouri 63304, United States
  • Arch Clinical Trials
    Saint Louis, Missouri 63125, United States
  • PsychCare Consultants Research
    Saint Louis, Missouri 63128, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11516, United States
  • New York State Psychiatric Institute
    New York, New York 10032, United States
  • Manhattan Behavioral Medicine PLLC
    New York, New York 10036, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
  • University Hills Clinical Research
    Irving, Texas 75062, United States
  • Pillar Clinical Research, LLC
    Richardson, Texas 75080, United States
  • @Health Texas
    Richmond, Texas 77407, United States
  • University of Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • Dr. Alexander McIntyre Inc.
    Penticton, British Columbia V2A 4M4, Canada
  • The Medical Arts Health Research Group
    Vancouver, British Columbia V7T 1C5, Canada
  • Chatham-Kent Clinical Trials Research Centre
    Chatham, Ontario N7L 1C1, Canada
  • Centre for Addiction and Mental Health (CAMH)
    Toronto, Ontario M6J 1H4, Canada
  • IUSMM Institut Universitaire en Sante Mentale de Montreal
    Montreal, Quebec H1N 3M5, Canada
  • HOP la Colombière
    Montpellier, 34295, France
  • GHU Paris Psychiatrie et Neurosciences
    Paris, 75674, France
  • HOP Guillaume Régnier
    Rennes, 35703, France
  • HOP Nord
    Saint-Priest-en-Jarez, 42270, France
  • HOP Sainte Musse
    Toulon, 83100, France
  • Okehazama Hospital Fujita Kokoro Care Center
    Aichi, Toyoake, 470-1168, Japan
  • Fujita Health University Hospital
    Aichi, Toyoake, 470-1192, Japan
  • National Center for Global Health and Medicine Kohnodai Hospital
    Chiba, Ichikawa, 272-8516, Japan
  • Fukuoka University Hospital
    Fukuoka, Fukuoka, 814-0180, Japan
  • Kuramitsu Hospital
    Fukuoka, Fukuoka, 819-0037, Japan
  • Soushu Hospital
    Kanagawa, Atsugi, 243-0201, Japan
  • Kishiro Mental Clinic
    Kanagawa, Kawasaki, 214-0014, Japan
  • Nara Medical University Hospital
    Nara, Kashihara, 634-8522, Japan
  • National Hospital Organization Hizen Psychiatric Medical Center
    Saga, Kanzaki-gun, 842-0192, Japan
  • National Center Neurology and Psychiatry
    Tokyo, Kodaira, 187-8851, Japan
  • Chonnam National University Hospital
    Gwangju, 61453, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam, 13620, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Hospital Universitario Marqués de Valdecilla
    Santander, 39008, Spain
  • NCKUH
    Tainan, 704, Taiwan
  • Taoyuan Psychiatric Center
    Taoyuan, 33058, Taiwan
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a "Document Sharing Agreement". For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Mar 2021, 39 months.

Results were first posted in Apr 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2017
First posted
Nov 22, 2017
StartActual
Dec 7, 2017
Primary completionActual
Mar 10, 2021
CompletionActual
Mar 31, 2021
Results first posted
Apr 4, 2022
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03351244
Responsible party
Sponsor
First posted
Nov 22, 2017
Start date
Dec 7, 2017
Primary completion
Mar 10, 2021
Completion
Mar 31, 2021
Results posted
Apr 4, 2022
Last update
May 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI 409306

Start the discussion